Solid Biosciences Inc.
SLDB
Rank in Stocks
#10042
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating... Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
Share Price
$7.02
Last synced: 2026-11-09
Market Cap
$752.72M
Change (1 day)
6.53%
Change (1 year)
54.97%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Solid Biosciences Inc. (SLDB)
Category
Healthcare
EPS for Solid Biosciences Inc. (SLDB)
EPS as of September 2026 TTM: $-1.79
According to Solid Biosciences Inc.'s latest financial reports, its current EPS (TTM) is $-1.79. At the end of 2025 the company had an EPS of $-1.99, an increase over its 2024 EPS of $-3.06.
EPS history for Solid Biosciences Inc. from 2015 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.79 | -10.05% |
| 2025 | $-1.99 | -34.97% |
| 2024 | $-3.06 | -36.65% |
| 2023 | $-4.83 | -52.18% |
| 2022 | $-10.10 | -0.39% |
| 2021 | $-10.14 | -60.24% |
| 2020 | $-25.50 | -40.77% |
| 2019 | $-43.05 | 27.63% |
| 2018 | $-33.73 | 39.04% |
| 2017 | $-24.26 | 44.40% |
| 2016 | $-16.80 | 238.03% |
| 2015 | $-4.97 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -974.86% |
US
|
|
| $-7.07 | 294.97% |
US
|
|
| $-5.29 | 195.53% |
AU
|
|
| $12.88 | -819.56% |
BE
|
|
| $21.56 | -1,304.47% |
NL
|
Questions about Solid Biosciences Inc.'s earnings per share (EPS)
What is Solid Biosciences Inc.'s earnings per share (EPS)?
Solid Biosciences Inc.'s earnings per share (EPS) over the last twelve months is $-1.79, as of Sep 2026.
What was Solid Biosciences Inc.'s earnings per share (EPS) in 2025?
In 2025, Solid Biosciences Inc.'s earnings per share (EPS) was $-1.99, compared with $-3.06 in 2024.
How has Solid Biosciences Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Solid Biosciences Inc.'s earnings per share (EPS) was highest in 2025 ($-1.99) and lowest in 2020 ($-25.50).
How does Solid Biosciences Inc.'s earnings per share (EPS) compare with similar companies?
Solid Biosciences Inc.'s earnings per share (EPS) ($-1.79) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.